Zusammenfassung
Sowohl klinische als auch vor allem experimentelle Studien lassen den Schluß zu, daß VPA teratogene Effekte induzieren kann. Muß diese Substanz während der Schwangerschaft verabreicht werden, soll die Dosis möglichst gering gehalten und auf mehrere tägliche Gaben pro Tag aufgeteilt werden. Experimentelle Studien zeigen eine hohe Strukturspezifität des teratogenen Effekts, so daß möglich erscheint, antiepileptisch wirksame Substanzen mit niedriger teratogener Potenz wie das 2–en-VPA zu entwickeln. Der Mechanismus des teratogenen Effekts ist noch unbekannt, eine Beeinflussung des Folatstoffwechsels ist wahrscheinlich.
Danksagung: Diese Arbeiten wurden von der Deutschen Forschungsgemeinschaft (SFB 174, Projekt C6), vom Bundesgesundheitsamt Berlin (ZEBET) sowie der Freien Universitat Berlin und von Desitin Arzneimittel GmbH, Hamburg, unterstützt.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Ardinger HH, Atkin JF, Blackston RD, Elsas LJ, Clarren SK, Livingstone S, Flannery DB, Pellock JM, Harrod MJ, Lammer EJ, Majewski F, Schinzel A, Toriello HV, Hanson JW (1988) Verification of the fetal valproate syndrome phenotype. Amer J Med Gen 29:171–185
Dencker L, Nau H, D’Argy R (1990) Marked accumulation of valproic acid in embryonic neuroepithelium of the mouse during early organogenesis. Teratology 41:699–706
DiLiberti JH. Farndon PA, Dennis NR, Curry CJR (1984) The fetal valproate syndrome. Amer J Med Gen 19:473–481
Ehlers K, Stiirje H, Merker H-J, Nau H (1991) Valproic acid-induced spina bifida: A mouse model. Teratology 45:145–154
Elmazar MMA, Thiel R, Nau H (1992) Effect of supplementation with folinic acid, vitamin B6 and vitamin B12 on valproic acid-induced teratogenesis in mice. Fund Appl Toxicol 18:389–394
Hauck RS, Nau H (1989) Asymmetric synthesis and enantioselective teratogenicity of 2– n-propyl-4–pentenoic acid (4–en-VPA), an active metabolite of the anticonvulsant drug, valproic acid. Toxicol Let 49:41–48
Hauck RS, Elmazar MMA, Nau H (1991) On the development of alternative antiepileptic drugs: Lack of enantioselectivity of the anticonvulsant activity, in contrast to teratogenicity of 2–n-propyl-4–pentenoic acid and 2–n-propyl-4–pentynoic acid, analogues of the anticonvulsant drug valproic acid. Naturwissenschaften 78:272–274
Hendrickx AG, Nau H, Binkerd P, Rowland JM, Rowland JR, Cukierski MJ, Cukierski MA (1988) Valproic acid developmental toxicity and pharmacokinetics in the Rhesus monkey: An interspecies comparison. Teratology 38:329–345
Jäger-Roman E, Deichl A, Jakob S, Hartmann A-M, Koch S, Rating D, Steldinger R, Nau H, Helge H (1986) Fetal growth, major malformations and minor anomalies in infants born to women receiving valproic acid. J Pediatr 108:997–1004
Lindout D, Schmidt D (1986) In utero exposure to valproate and neural tube defects. Lancet 1:1392–1393
Löscher W, Nau H (1985) Pharmacological evaluation of various metabolites and analogues of valproic acid-anticonvulsant and toxic potencies in mice. Neuropharmacol 24:427–435
Nau H, Hauck R-S, Ehlers K (1991) Valproic acid-induced neural tube defects in mouse and humans: Aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol 69:310–321 Nau H (1988) Pharmakokinetische Grundlagen der Teratogenität. Internist 29:179–192
Nau H (1987) Valproinsäure-Serumkonzentrationen bei Monotherapie mit Einmal-, Zweimal-und Mehrfachgabe pro Tag. Nervenarzt 58:459
Nau H (1985) Teratogenic valproic acid concentrations: Infusion by implanted minipumps vs. conventional injection regimen in the mouse. Toxicol Appl Pharmacol 80:243–250
Nau H (1986) Transfer of valproic acid and its main active unsaturated metabolite to the gestational tissue: Correlation with neural tube defect formation in the mouse. Teratology 33:21–27
Nau H, Löscher W (1986) Pharmacologic evaluation of various metabolites and analogs of valproic acid: Teratogenic potencies in mice. Fundam Appl Toxicol 6:669–676
Nau H, Siemes H (1992) Differentiation between valproic acid-induced anticonvulsant effect, teratogenicity and hepatotoxicity: Aspects of species variation, pharmacokinetics, metabolism and implications of structural specificity for the development of alternative antiepileptic agents such as 2–en-VPA. Pharmac Weekbl 14:101–107
Nau H, Scott WJ (1986) Weak acids may act as teratogens by accumulating in the basic milieu of the early mammalian embryo. Nature 323:276–278
Nau H, Rating D, Koch S, Häuser I, Helge H (1981) Valproic acid and its metabolites: Placental transfer, neonatal pharmacokinetics, transfer via mothers milk and clinical status in neonates of epileptic mothers. J Pharmacol Exp Therap 219:768–777
Robert E (1988) Valproic acid as a human teratogen. Cong Anom 28 (Suppl):71–80
Trotz M, Wegner C, Nau H (1987) Valproic acid-induced neural tube defects: Reduction by folinic acid in the mouse. Life Sci 41:103–110
Vorhees CV, Acuff-Smith KD, Weisenburger WP, Minck DR, Berry JS, Setchell KDR, Nau H (1991) Lack of teratogenicity of trans-2–ene-valproic acid compared to valproic acid in rats. Teratology 43:583–590
Wegner C, Nau H (1991) Diurnal variation of folate concentrations in mouse embryo and plasma: the protective effect of folinic acid on valproic acid-induced teratogenicity is time-dependent. Repr Toxicol 5:465–171
Wegner C, Nau H (1992) Alteration of embryonic folate metabolism by valproic acid during embryogenesis: Implications for the mechanism of teratogenesis. Neurology 42 (Suppl 5): 17–24
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Nau, H. (1992). Experimentelle Studien zur Teratogenität von Valproinsäure. In: Krämer, G., Laub, M.C. (eds) Valproinsäure. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-97843-2_30
Download citation
DOI: https://doi.org/10.1007/978-3-642-97843-2_30
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-97844-9
Online ISBN: 978-3-642-97843-2
eBook Packages: Springer Book Archive